Nothing Special   »   [go: up one dir, main page]

CN110573521A - 4’-硫代核苷的新型化合物的制备方法和此制备方法中的中间体 - Google Patents

4’-硫代核苷的新型化合物的制备方法和此制备方法中的中间体 Download PDF

Info

Publication number
CN110573521A
CN110573521A CN201880028331.2A CN201880028331A CN110573521A CN 110573521 A CN110573521 A CN 110573521A CN 201880028331 A CN201880028331 A CN 201880028331A CN 110573521 A CN110573521 A CN 110573521A
Authority
CN
China
Prior art keywords
compound
formula
group
optionally substituted
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880028331.2A
Other languages
English (en)
Other versions
CN110573521B (zh
Inventor
周江峰
梁玉峰
王强
王涛
韩维彪
李友强
魏海东
葛建华
赵忠琼
文乾映
吴灵静
田强
赵明亮
曾宏
蔡家强
王利春
王晶翼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Original Assignee
Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Kelun Biotech Biopharmaceutical Co Ltd filed Critical Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Publication of CN110573521A publication Critical patent/CN110573521A/zh
Application granted granted Critical
Publication of CN110573521B publication Critical patent/CN110573521B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Description

PCT国内申请，说明书已公开。

Claims (17)

  1. PCT国内申请，权利要求书已公开。
CN201880028331.2A 2017-06-29 2018-06-15 4’-硫代核苷的新型化合物的制备方法和此制备方法中的中间体 Active CN110573521B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710513557 2017-06-29
CN2017105135579 2017-06-29
PCT/CN2018/091514 WO2019001292A1 (zh) 2017-06-29 2018-06-15 4'-硫代核苷的新型化合物的制备方法和此制备方法中的中间体

Publications (2)

Publication Number Publication Date
CN110573521A true CN110573521A (zh) 2019-12-13
CN110573521B CN110573521B (zh) 2023-04-21

Family

ID=64741031

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880028331.2A Active CN110573521B (zh) 2017-06-29 2018-06-15 4’-硫代核苷的新型化合物的制备方法和此制备方法中的中间体

Country Status (2)

Country Link
CN (1) CN110573521B (zh)
WO (1) WO2019001292A1 (zh)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014189499A (ja) * 2013-03-26 2014-10-06 Taiho Yakuhin Kogyo Kk 新規なピリミジンヌクレオシドのシリル誘導体
CN104327137A (zh) * 2014-11-07 2015-02-04 王彩琴 一种氘代索菲布韦及其用途
CN104540803A (zh) * 2012-08-13 2015-04-22 富士胶片株式会社 1-(2-脱氧-2-氟-4-硫代-β-D-阿拉伯呋喃糖基)胞嘧啶的合成中间体和硫代核苷的合成中间体以及它们的制造方法
WO2016155593A1 (zh) * 2015-04-03 2016-10-06 四川科伦药物研究院有限公司 4'-硫代核苷的新型化合物及其制备方法、药物组合物和应用
CN106083962A (zh) * 2016-06-08 2016-11-09 成都倍特药业有限公司 一种具有环磷酰胺结构的化合物及其制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014197578A1 (en) * 2013-06-05 2014-12-11 Idenix Pharmaceuticals, Inc. 1',4'-thio nucleosides for the treatment of hcv

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104540803A (zh) * 2012-08-13 2015-04-22 富士胶片株式会社 1-(2-脱氧-2-氟-4-硫代-β-D-阿拉伯呋喃糖基)胞嘧啶的合成中间体和硫代核苷的合成中间体以及它们的制造方法
JP2014189499A (ja) * 2013-03-26 2014-10-06 Taiho Yakuhin Kogyo Kk 新規なピリミジンヌクレオシドのシリル誘導体
CN104327137A (zh) * 2014-11-07 2015-02-04 王彩琴 一种氘代索菲布韦及其用途
WO2016155593A1 (zh) * 2015-04-03 2016-10-06 四川科伦药物研究院有限公司 4'-硫代核苷的新型化合物及其制备方法、药物组合物和应用
CN106083962A (zh) * 2016-06-08 2016-11-09 成都倍特药业有限公司 一种具有环磷酰胺结构的化合物及其制备方法

Also Published As

Publication number Publication date
CN110573521B (zh) 2023-04-21
WO2019001292A1 (zh) 2019-01-03

Similar Documents

Publication Publication Date Title
TWI658042B (zh) 雜環化合物的合成
US8895723B2 (en) Methods of preparing substituted nucleotide analogs
EP3398952B1 (en) Synthesis process of ruxolitinib
CA3079019C (en) Process for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
ES2536923T3 (es) Proceso e intermedios para preparar inhibidores de la integrasa del VIH
CA3090280A1 (en) Methods and intermediates for preparing therapeutic compounds useful in the treatment of retroviridae viral infection
JP6800334B2 (ja) Ｂｔｋ阻害剤を調製するプロセス
TW201625659A (zh) 製備經取代之核苷酸類似物之方法
JP2015502932A (ja) 置換された５−フルオロ−１ｈ−ピラゾロピリジン類を製造するための方法
MX2009000157A (es) Sintesis de dietil{[5"-(3-fluorofenil)-piridin-2-il]metil}fosfonat o usado en la sintesis de analogos de himbacina.
US6429315B1 (en) Process for preparing N6-substituted adenosine derivatives
TWI545114B (zh) 製備聯苯基咪唑化合物之方法
CN110573521A (zh) 4’-硫代核苷的新型化合物的制备方法和此制备方法中的中间体
CN104710417B (zh) 氮杂吲哚类衍生物及其合成方法
CA2915841C (en) Method for the preparation of (1,2,4)-triazolo(4,3-a)pyridines
SE455502B (sv) Forfarande for deacylering av 1-acyl-2-imidazolin
EP2057166B1 (en) Process and intermediates for the synthesis of (3-alkyl-5-piperidin-1-yl-3,3a-dihydropyrazolo[1,5-a]pyrimidin-7-yl)-amino derivatives
CN109456257B (zh) 一种高收率2-氯-5-硝基吡啶的制备方法
CN107129495B (zh) 一种毒扁豆碱前体化合物的制备方法
JPS59144794A (ja) カルボン酸活性化剤
US5998614A (en) Preparation of asymmetric cyclic ureas using an alkali metal in liquid ammonia process
CN118702621A (zh) 一种尼可刹米的制备方法
KR20220101702A (ko) 크로만 화합물의 제조 공정
WO2024046221A1 (en) Egfr inhibitors and uses thereof
WO2024110863A1 (en) Process and intermediates for preparing ((1r,2s,4r)-4-((5-(4-((r)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl)-5-methylthiophene-2-carbonyl)pyrimidin-4-yl)amino)-2-hydroxycyclopentyl)methyl sulfamate

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant